MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

References

• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. The Company of Biologists Ltd; 2012;125(23):5591–5596.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–13. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, editors. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185–S198. Elsevier. doi:10.1016/j.semcancer.2015.03.004.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Figueiredo C, Azevedo R, Mousdell S, Resende-Lara P, Ireland L, Santos A, Girola N, Cunha RL, Schmid, MC, Polonelli L, et al. Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the anti-tumour immune response against metastatic melanoma. Front Immunol. 2018;9:1132. doi:10.3389/fimmu.2018.01132.
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Putty K, Rendon B, Lamont G, Faughn J, Mitchell R. Control of tumor-associated macrophage alternative activation by MIF. AACR; 2013190(6):2984–2993.
   Google Scholar
• Kindt N, Journe F, Laurent G, Saussez S. Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncol Lett. 2016;12(4):2247–2253. doi:10.3892/ol.2016.4929.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen T, Leng L, Fan J, Cao K, Duan Z, Zhang X, Shao C, Wu M, Tadmori I. MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res. 2012;72(11):2867–2878. doi:10.1158/0008-5472.CAN-11-3247.
   PubMed Web of Science ®Google Scholar
• Imaoka M, Tanese K, Masugi Y, Hayashi M, Sakamoto M. Macrophage migration inhibitory factor‐CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells. Cancer Sci. 2019;110(7):2273. doi:10.1111/cas.14038.
   PubMed Web of Science ®Google Scholar
• Romero-Garcia S, Moreno-Altamirano MMB, Prado-Garcia H, Sánchez-García FJ. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol. 2016;7:52. doi:10.3389/fimmu.2016.00052.
   PubMed Web of Science ®Google Scholar
• Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell surface CD74–MIF interactions drive melanoma survival in response to interferon-γ. J Invest Dermatol. 2015;135(11):2775–2784. doi:10.1038/jid.2015.204.
   PubMed Web of Science ®Google Scholar
• Gil-Yarom N, Radomir L, Sever L, Kramer MP, Lewinsky H, Bornstein C, Blecher-Gonen R, Barnett-Itzhaki Z, Mirkin V, Friedlander G. CD74 is a novel transcription regulator. Proc Natl Acad Sci. 2017;114(3):562–567. doi:10.1073/pnas.1612195114.
   PubMed Web of Science ®Google Scholar
• Chesney JA, Mitchell RA, Yaddanapudi K. Myeloid‐derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy. J Leukoc Biol. 2017;102:727–740.
   PubMed Web of Science ®Google Scholar
• Choi S, Kim H-R, Leng L, Kang I, Jorgensen WL, Cho C-S, Bucala R, Kim W-U. Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice. J Immunol. 2012;189(8):3905–3913. doi:10.4049/jimmunol.1102152.
   PubMed Web of Science ®Google Scholar
• Abe R, Peng T, Sailors J, Bucala R, Metz CN. Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol. 2001;166(2):747–753. doi:10.4049/jimmunol.166.2.747.
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Rendon BE, Lamont G, Kim EJ, Al Rayyan N, Richie J, Albeituni S, Waigel S, Wise A, Mitchell RA. MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation. Cancer Immunol Res. 2016;4(2):101–112. doi:10.1158/2326-6066.CIR-15-0070-T.
   PubMed Web of Science ®Google Scholar
• Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clin Cancer Res. 2016;22(12):3016–3024. doi:10.1158/1078-0432.CCR-15-2226.
   PubMed Web of Science ®Google Scholar
• Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010;70(24):10150–10160. doi:10.1158/0008-5472.CAN-10-1852.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. doi:10.1056/NEJMoa1414428.
   PubMed Web of Science ®Google Scholar
• Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 2016;76(23):6851–6863. doi:10.1158/0008-5472.CAN-16-1201.
   PubMed Web of Science ®Google Scholar
• Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, Zhu J. Exploring TCGA pan-cancer data at the UCSC cancer genomics browser. Sci Rep. 2013;3(1):2652. doi:10.1038/srep02652.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10. doi:10.1158/0008-5472.CAN-17-0307.
   PubMed Web of Science ®Google Scholar
• Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, Liu XS. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):1–8. doi:10.1186/s13073-020-0721-z.
   Web of Science ®Google Scholar
• Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang Z-Q, Reuben A, Cooper ZA. Melanoma evolves complete immunotherapy resistance through the acquisition of a hypermetabolic phenotype. Cancer Immunol Res. 2020;8(11):1365–1380. doi:10.1158/2326-6066.CIR-19-0005.
   PubMed Web of Science ®Google Scholar
• Wang Z-Q, Milne K, Webb JR, Watson PH. CD74 and intratumoral immune response in breast cancer. Oncotarget. 2017;8(8):12664. doi:10.18632/oncotarget.8610.
   PubMedGoogle Scholar
• Xu L, Li Y, Sun H, Zhen X, Qiao C, Tian S, Hou T. Current developments of macrophage migration inhibitory factor (MIF) inhibitors. Drug Discov Today. 2013;18(11–12):592–600. doi:10.1016/j.drudis.2012.12.013.
   PubMed Web of Science ®Google Scholar
• Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, Xie S, Guo L. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 201917(3):227–236.
   Web of Science ®Google Scholar
• Koch J, Dübel S, Usener D, Schadendorf D, Eichmüller S. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. J Invest Dermatol. 2003;121(1):198–206. doi:10.1046/j.1523-1747.2003.12318.x.
   PubMed Web of Science ®Google Scholar
• Zajac P, Schultz-Thater E, Tornillo L, Sadowski C, Trella E, Mengus C, Iezzi G, Spagnoli GC. MAGE-A antigens and cancer immunotherapy. Front Med. 2017;4:18. doi:10.3389/fmed.2017.00018.
   Web of Science ®Google Scholar
• Tun-Kyi A, Finn G, Greenwood A, Nowak M, Lee TH, Asara JM, Tsokos GC, Fitzgerald K, Israel E, Li X. Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon–mediated immunity. Nat Immunol. 2011;12(8):733. doi:10.1038/ni.2069.
   PubMed Web of Science ®Google Scholar
• Urban-Wojciuk Z, Khan MM, Oyler BL, Fåhraeus R, Marek-Trzonkowska NM, Nita-Lazar A, Hupp TR, Goodlett DR. The role of TLRs in anti-cancer immunity and tumor rejection. Front Immunol. 2019;10:2388. doi:10.3389/fimmu.2019.02388.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117(5):1184–1194. doi:10.1172/JCI31414.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018Oct;24(10):1550–1558.
   Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010.
   PubMed Web of Science ®Google Scholar
• Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012;3:274. doi:10.3389/fimmu.2012.00274.
   PubMed Web of Science ®Google Scholar
• Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim Y-S. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat Cell Biol. 2016;18(5):549. doi:10.1038/ncb3340.
   PubMed Web of Science ®Google Scholar
• Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–449. doi:10.1016/j.immuni.2015.09.001.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Mak TW. Fire and water: tumor cell adaptation to metabolic conditions. Exp Cell Res. 2017;356(2):204–208. doi:10.1016/j.yexcr.2017.04.029.
   PubMed Web of Science ®Google Scholar
• Kareva I, Hahnfeldt P. The emerging “hallmarks” of metabolic reprogramming and immune evasion: distinct or linked? Cancer Res. 2013;73(9):2737–2742. doi:10.1158/0008-5472.CAN-12-3696.
   PubMed Web of Science ®Google Scholar
• Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits E, Baruch EN, Tripple V, Arama-Chayoth M, Greenberg E. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell. 2019;179(1):236–50.e18. doi:10.1016/j.cell.2019.08.012.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309.
   PubMed Web of Science ®Google Scholar
• Paudel BB, Quaranta V. Metabolic plasticity meets gene regulation. Proc Natl Acad Sci. 2019;116(9):3370–3372. doi:10.1073/pnas.1900169116.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang J, Xie F, Peng J, Wu X. Macrophage migration inhibitory factor promotes Warburg effect via activation of the NF‑κB/HIF‑1α pathway in lung cancer. Int J Mol Med. 2018;41:1062–1068.
   PubMed Web of Science ®Google Scholar
• Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. AACR; 2012 Oct 15;18(20):5585–5594.
   Google Scholar
• Wang Y, Wang H, Yao H, Li C, Fang J-Y J-Y, Xu J. Regulation of PD-L1: emerging routes for targeting tumor immune evasion. Front Pharmacol. 2018;9:536. doi:10.3389/fphar.2018.00536.
   PubMed Web of Science ®Google Scholar
• San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect. Carcinogenesis. 2017;38:119–133.
   PubMed Web of Science ®Google Scholar
• Simpson KD, Templeton DJ, Cross JV. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol. 2012;189(12):5533–5540. doi:10.4049/jimmunol.1201161.
   PubMed Web of Science ®Google Scholar
• Waigel S, Rendon BE, Lamont G, Richie J, Mitchell RA, Yaddanapudi K. MIF inhibition reverts the gene expression profile of human melanoma cell line-induced MDSCs to normal monocytes. Genomics Data. 2016;7:240–242.
   PubMedGoogle Scholar
• Esnault S, Braun RK, Shen Z-J, Xiang Z, Heninger E, Love RB, Sandor M, Malter JS. Pin1 modulates the type 1 immune response. PLoS One. 2007;2:2. doi:10.1371/journal.pone.0000226.
   Web of Science ®Google Scholar
• Mangano K, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, Petralia MC, Fagone P, Nicoletti F. Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget. 2018;9:17951.
   PubMedGoogle Scholar
• Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM. Milatuzumab–SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther. 2013;12(6):968–978. doi:10.1158/1535-7163.MCT-12-1170.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan‐Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM. Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013;163(4):478–486. doi:10.1111/bjh.12565.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Patel M, Sachdev J, Hart L, Halama N, Ramanathan R, Sarantopoulos J, Liu X, Yazji S, Jäger D. Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: final results of first-in-human phase 1 study. Ann Oncol. 2016;27(suppl_6):vi116. doi:10.1093/annonc/mdw368.08.
   Google Scholar
• Fu W, Ergun A, Lu T, Hill JA, Haxhinasto S, Fassett MS, Gazit R, Adoro S, Glimcher L, Chan S, et al. A multiply redundant genetic switch’locks in’the transcriptional signature of regulatory T cells. Nat Immunol. 2012;13:972.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6(11):1142–1151. doi:10.1038/ni1263.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175:998–1013.e20.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ha S-J, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670–684. doi:10.1016/j.immuni.2007.09.006.
   PubMed Web of Science ®Google Scholar
• Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, Tsouko E, Welsh JW, Cortez MA. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019;195:162–171. doi:10.1016/j.pharmthera.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685–3692. doi:10.1172/JCI69741.
   PubMed Web of Science ®Google Scholar
• Spencer NY, Stanton RC, editors. The Warburg effect, lactate, and nearly a century of trying to cure cancer. Semin Nephrol. 2019;39(4):380–393. Elsevier. doi:10.1016/j.semnephrol.2019.04.007.
   PubMed Web of Science ®Google Scholar
• Zhu G, Tang Y, Geng N, Zheng M, Jiang J, Li L, Li K, Lei Z, Chen W, Fan Y. HIF-α/MIF and NF-κB/IL-6 axes contribute to the recruitment of CD11b+Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC. Neoplasia (New York, NY). 2014;16(2):168. doi:10.1593/neo.132034.
   PubMed Web of Science ®Google Scholar
• Wigerup C, Påhlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016;164:152–169. doi:10.1016/j.pharmthera.2016.04.009.
   PubMed Web of Science ®Google Scholar